PATIENT PORTAL 401.444.7959

Clinical Trials

Alopecia Areata

Brown Dermatology is working on getting new Alopecia trials to offer our patients. If you would like to be contacted about upcoming trials please call Justine Bernier at (401) 606-4696.

Atopic Dermatitis

The purpose of this research study is to compare the effects of the study drug, PF‑04965842, with a placebo to find out which is better for treating atopic dermatitis. PF-04965842 is a blocker of an enzyme called Janus kinase, which acts like a switch for the cells of the immune system (the body’s defense against infection and inflammation).  By turning off this switch, the cells of the immune system are expected to produce fewer chemicals believed to cause atopic dermatitis. For further information, please contact Justine Bernier at (401) 606-4696.

Cutaneous Squamous Cell Carcinoma In Situ

The study involves the treatment of cutaneous squamous cell carcinoma in situ with photodynamic therapy utilizing aminolevulinic acid plus blue light.  Patients must be over 18 years old and with a diagnosis of squamous cell carcinoma in situ, with no evidence of invasion or microinvasion on pathology. Lesions clinically must be less than 2cm (approximately 3/4th of an inch). The squamous cell carcinoma in situ may not be location on the head, neck, hands, or feet, and patients cannot have a history of adverse reactions to topical aminolevulinic acid, blue light, or Tegaderm. For further information, please contact Justine Bernier at (401) 606-4696.

Hidradenitis Suppurativa

The purpose of this study is to find out how effective, safe, and tolerable bimekizumab is for the treatment of HS. Bimekizumab is an investigational antibody (a protein involved in directing the body’s defense mechanisms, like inflammation), which blocks a naturally-occurring substance called interleukin-17 (IL-17). Interleukin-17 is involved in HS and other inflammatory diseases. Studies in animals showed that blocking of IL-17 might help the treatment of such inflammatory diseases. In this study, FDA approved Adalimumab, will also be used. Some participants will receive bimekizumab as part of this research study and some will receive Adalimumab. For further information, please contact Justine Bernier at (401) 606-4696.

Hidradenitis Suppurativa (Requiring Surgery)

This study is looking at an FDA approved drug called Humira® (adalimumab) compared to placebo in subjects with hidradenitis suppurativa (HS). Adalimumab may reduce the number of nodules and abscesses and the pain that is associated with the disease. The study aims to…

  • Assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe hidradenitis suppurativa who need surgery for a particular wound.
  • Assess the impact of adalimumab on the planned hidradenitis suppurativa surgical site before surgery and evaluate the safety and efficacy of adalimumab when used after surgery.

For further information, please contact Justine Bernier at (401) 606-4696.

Moles Self Imaging

The study involves the evaluation of the utility and efficacy of the Self-Imaging of Moles (SIM) Method as a body photography tool to be used in a remote setting to rapidly and accurately assess the number of nevi a patient has on a body site of interest. Patients must be at least 18 and own a personal cell phone with a camera. For further information, please contact Justine Bernier at (401) 606-4696.

Psoriasis Registry

The study involves the creation of a registry of patients with psoriasis whom were started or plan to be started on a new biological medication in the past 12 months.  Patients must be over 18 years old and diagnosed by a Dermatologist with psoriasis. Patients must be started on or switched to a biological medication within the last 12 months. Patients must be willing to fill out questionnaires every 6-18 months. For further information, please contact Justine Bernier at (401) 606-4696.

Psoriasis Self Imaging

The study involves the evaluation of the utility and efficacy of the Psoriatic Self-Photography Method (PSPM) as a body photography tool to be used in the patient home setting for providers to dynamically monitor lesions and assess the extent and severity of disease. Patients must be at least 18 years old, be diagnosed by a Dermatologist with psoriasis and own a personal cell phone with a camera. For further information, please contact Justine Bernier at (401) 606-4696.

Skin Disease Biorepository

A registry for new and existing patients 18 years of age and older, seen for treatment and follow-up of their diagnosed skin disease, such as skin cancer, psoriatic arthritis, psoriasis, vitiligo, hidradenitis suppurativa, atopic dermatitis, alopecia areata, atypical nevi, cutaneous lupus erythematosus, dermatomyositis, scleroderma, pemphigoid and lichen planus. This study will take place at the Brown Dermatology clinic at 593 Eddy Street, APC-10 and satellite offices and at the outpatient dermatology clinics at LPG Dermatology, 950 Warren Avenue. The collected information will help physicians better understand, prevent and diagnose, or treat a variety of diseases and conditions. For further information, please contact Justine Bernier at (401) 606-4696.